Primary Biliary Cholangitis Therapeutics Market Size, Share & Trends Analysis Report, By Drug Type (Primary Drug, Secondary Drug), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Market Size & Trends

The global primary biliary cholangitis therapeutics market size was valued at USD 686.5 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.5% from 2023 to 2030. Primary biliary cholangitis (PBC) is an autoimmune liver disease that affects small bile ducts. This condition is characterized by the gradual deterioration of these bile ducts, leading to compromised bile flow and subsequent harm to the liver. The precise cause of PBC remains unidentified; however, it is believed to arise from genetic, environmental, and immune system elements. Specific genetic predispositions and environmental triggers, such as infections or exposure to harmful substances, may contribute to the onset of the disease.

The pharmaceutical industry is actively investing in research and development activities to gain a deeper understanding of the underlying mechanisms of PBC and create effective therapies. This involves the exploration of new drugs, combinations of therapies, and effective clinical trials. Therefore, the increased focus on research and development for primary biliary cholangitis therapeutics is propelling the expansion of the primary biliary cholangitis therapeutics market over the forecast period.

Global supply chains, including pharmaceutical manufacturing and distribution, were adversely affected by the disturbances caused by the COVID-19 pandemic. The imposition of movement restrictions, including imports and exports, and the reduced capacity of manufacturing plants negatively impacted the manufacturing and distribution of therapies for primary biliary cholangitis (PBC). Consequently, the COVID-19 outbreak had an adverse effect on the market.

Drug Type Insights

Based on the drug type, the market is segmented into primary and secondary drug types. The primary drug type segment held the largest market share in 2022 due to the widespread use of primary medication for treating PBC and its proven effectiveness against the disease.

Distribution Channel Insights

On the basis of distribution channels, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The drug stores and retail pharmacies segment dominated the market in 2022. However, the online pharmacies segment is anticipated to grow at the fastest CAGR from 2023 to 2030. This can be attributed to the increasing penetration of the internet, ease of use and payment models, and, overall, the rapidly growing e-commerce trend, coupled with promotional offers and discounts that most e-commerce platforms offer.

Regional Insights

North America dominated the market in 2022. A large patient pool and the presence of established market players are anticipated to further strengthen market growth in this region. The market is being driven by increased clinical trials, the availability of advanced healthcare facilities, and significant healthcare investments by government organizations in the region. Additionally, the favorable reimbursement system facilitates keeping the out-of-pocket expenses for patients at a minimum, thus making the treatment accessible to the large patient pool.

Key Companies & Market Share Insights

Key players operating in the market are Lupin, ABC Farmaceutici S.p.a., Intercept Pharmaceuticals, Inc., Alkem Laboratories Limited, GENFIT, Leeford Healthcare Ltd, Ipsen Pharma, Zydus Lifesciences Limited, and Sun Pharmaceutical Industries Ltd. The following are some instances of strategic initiatives:

• In March 2023, Ipsen Pharma acquired Albireo Pharma, Inc. The latter is a leading innovator in bile-acid modulators to treat rare liver conditions. This acquisition is anticipated to expand Ipsen’s rare disease therapeutics product offerings.

• In May 2022, Advanz Pharma acquired the rights to a few products from Intercept Pharmaceuticals, Inc. This includes the rights for Advanz to commercialize the orphan drug Ocaliva outside the U.S.